ZEN-3694

HealthScout AI summary: Asymptomatic men with metastatic castration‑resistant prostate cancer progressing after a next‑generation AR inhibitor (with ongoing ADT; prior taxane/PARP/radiopharmaceuticals allowed) receive sequential therapy starting with high‑dose testosterone plus the BET inhibitor ZEN‑3694 (targets BRD2/3/4/BRDT to suppress MYC/AR signaling), then transition at radiographic progression to enzalutamide plus ZEN‑3694. Aims to enhance disease control and potentially resensitize tumors to AR‑targeted therapy; key labs/organ function required, ECOG 0–2, PSA ≥1 ng/mL.

ClinicalTrials.gov ID: NCT06922318

HealthScout AI summary: This trial enrolls adults with refractory, BRAF V600E-mutant metastatic colorectal cancer who have previously tolerated encorafenib plus cetuximab, and evaluates the addition of ZEN003694, a pan-BET bromodomain inhibitor, to ongoing encorafenib and cetuximab therapy. Patients must have good performance status and adequate organ function, and may have stable or treated brain metastases.

ClinicalTrials.gov ID: NCT06102902

HealthScout AI summary: Adults with recurrent clear cell or endometrioid ovarian carcinoma, platinum‑resistant HGSOC (dose‑escalation only), or recurrent FIGO grade 1 endometrioid/clear cell endometrial carcinoma receive oral tuvusertib (ATR inhibitor) plus ZEN‑3694 (pan‑BET inhibitor), with biomarker‑driven expansion enrolling both ARID1A‑mutated and ARID1A‑wild‑type cohorts. Aims include defining RP2D and assessing safety and preliminary activity, with mandated biopsies to explore pharmacodynamic effects and ARID1A‑related response.

ClinicalTrials.gov ID: NCT05950464

HealthScout AI summary: This trial enrolls adults with metastatic or unresectable solid tumors—including those with prior exposure to fluorouracil or capecitabine—to receive the BET bromodomain inhibitor ZEN003694 (which disrupts BRD4-mediated oncogenic transcription) in combination with capecitabine. Expansion cohorts specifically include metastatic colorectal cancer.

ClinicalTrials.gov ID: NCT05803382

HealthScout AI summary: This trial enrolls patients aged 12 and older with metastatic or unresectable NUT carcinoma, breast cancer, or other solid tumors who have no standard treatments remaining, including those previously treated with BET or CDK4/6 inhibitors. Participants receive oral ZEN003694, an investigational BET bromodomain inhibitor targeting oncogenic gene transcription, in combination with the CDK4/6 inhibitor abemaciclib.

ClinicalTrials.gov ID: NCT05372640

HealthScout AI summary: This trial enrolls adults with unresectable locally advanced or metastatic triple-negative breast cancer—including those with stable CNS metastases—to receive a combination of the BET bromodomain inhibitor ZEN003694 (targets epigenetic regulation), pembrolizumab, and nab-paclitaxel. Dose escalation includes any prior therapy and PD-L1 status, while expansion focuses on PD-L1–negative patients with limited prior lines and biopsy-accessible disease.

ClinicalTrials.gov ID: NCT05422794

HealthScout AI summary: Single-arm study for adult women with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma (platinum-sensitive or -resistant) with prior PARP inhibitor exposure, ECOG 0–1, and measurable disease. Patients receive oral ZEN003694 (pan-BET bromodomain inhibitor targeting BRD2/3/4/BRDT to downregulate HR/MYC programs) plus talazoparib (PARP inhibitor) in 28-day cycles; BRCA status known but not restricted.

ClinicalTrials.gov ID: NCT05071937

HealthScout AI summary: Adults with advanced/refractory solid tumors or lymphomas (all B- and T-cell subtypes except NK-cell) receive oral ZEN003694 (pan-BET bromodomain inhibitor targeting BRD2/3/4/BRDT) plus entinostat (class I HDAC inhibitor) after a brief monotherapy run-in; phase 2 focuses on unresectable/metastatic pancreatic cancer refractory to standard therapy. Combination is given in 28‑day cycles until progression or toxicity; treated/stable brain mets allowed, ECOG 0–2, prior systemic therapy required.

ClinicalTrials.gov ID: NCT05053971

HealthScout AI summary: Eligible patients are adults with advanced or metastatic solid tumors harboring RAS pathway alterations (KRAS, NRAS, HRAS, BRAF, or NF1), including those with triple negative breast cancer, who have progressed after standard therapy. Treatment consists of the BET inhibitor ZEN003694 (targets transcriptional regulation) in combination with the MEK inhibitor binimetinib, both given orally.

ClinicalTrials.gov ID: NCT05111561

HealthScout AI summary: Adults with metastatic or recurrent solid tumors lacking effective options (dose escalation) and an expansion cohort of recurrent, platinum‑resistant BRCA‑wild‑type epithelial ovarian cancer receive the oral pan‑BET inhibitor ZEN003694 (targets BRD2/3/4/BRDT; suppresses MYC and HR gene expression) combined with nivolumab, with or without low‑dose ipilimumab. Prior PD‑1/PD‑L1/CTLA‑4 therapy is generally excluded, ECOG 0–1 and measurable/biopsiable disease required.

ClinicalTrials.gov ID: NCT04840589

HealthScout AI summary: Men with metastatic castration-resistant prostate cancer progressing on abiraterone (ECOG 0–1, on continuous ADT, no prior second‑generation AR inhibitor or mCRPC chemotherapy) are randomized to enzalutamide alone versus enzalutamide plus ZEN003694, an oral pan-BET bromodomain inhibitor (BRD2/3/4/BRDT) aiming to suppress AR/MYC-driven transcription. Two predefined cohorts (poor vs good prior abiraterone responders) are included; crossover from control at radiographic progression is allowed.

ClinicalTrials.gov ID: NCT04986423